PubMed ID:
28985268
Public Release Type:
Journal
Publication Year: 2017
DOI:
https://doi.org/10.1093/ajh/hpx138
Authors:
Still Carolyn H, Rodriguez Carlos J, Wright Jackson T, Craven Timothy E, Bress Adam P, Chertow Glenn M, Whelton Paul K, Whittle Jeffrey C, Freedman Barry I, Johnson Karen C, Foy Capri G, He Jiang, Kostis John B, Lash James P, Pedley Carolyn F, Pisoni Roberto, Powell James R, Wall Barry M
Request IDs:
20271
Studies:
African American Study of Kidney Disease and Hypertension Study (Clinical Trial)
The Systolic Blood Pressure Intervention Trial (SPRINT) showed that targeting a systolic blood pressure (SBP) of ≤ 120 mm Hg (intensive treatment) reduced cardiovascular disease (CVD) events compared to SBP of ≤ 140 mm Hg (standard treatment); however, it is unclear if this effect is similar in all racial/ethnic groups.